Named on one round in the feed.
Since 2026-10-16
| Company | Round | Amount | Announced | Role |
|---|---|---|---|---|
Estuary Biotherapeutics, Inc. A biotechnology company developing genetic medicines for patients with serious kidney diseases | Series A Verified against 2 sources | $93M | 2026-10-16 | [ PART ] |